Outcomes of STEMI Patients in COVID-19 Pandemic: A Systematic Review and Meta-Analysis

Shiva Khaleghparast1, Majid Maleki2, Fereidoun Noohi2

  • 1Cardiovascular Nursing Research Center, Rajaie Cardiovascular Medical and Research Center, Iran University of Medical Sciences, Tehran, Iran.

PubMed

Insights

The COVID-19 pandemic led to worse outcomes for ST-segment elevation myocardial infarction (STEMI) patients, with increased mortality and longer door-to-balloon times. Hospital stays were not significantly affected, but further research is needed.

Area of Science:

  • Cardiology
  • Public Health
  • Epidemiology

Background:

  • The COVID-19 pandemic significantly strained global health systems.
  • Cardiac patients, particularly those with ST-segment elevation myocardial infarction (STEMI), experienced adverse effects due to healthcare prioritization.
  • Limited data exists on the in-hospital outcomes for STEMI patients during the pandemic.

Purpose of the Study:

  • To systematically review and analyze the in-hospital outcomes of STEMI patients during the COVID-19 pandemic.
  • To compare mortality, length of stay, and door-to-balloon times for STEMI patients before and during the pandemic.

Main Methods:

  • A systematic literature search was conducted across major databases (MEDLINE, Web of Science, Scopus, Embase) up to January 10, 2021.
  • Studies with over twenty participants reporting in-hospital mortality, length of stay, or door-to-balloon time were included, adhering to PRISMA guidelines.
  • Meta-analysis was performed to pool data on key outcomes.

Main Results:

  • The meta-analysis included 12 studies with 21,170 patients.
  • A significant increase in pandemic-related mortality was observed (OR=1.24; 95% CI: 1.07-1.43).
  • Door-to-balloon times significantly increased during the pandemic (SMD= 0.46; 95% CI: 0.03-0.89), while length of hospital stay showed no significant change (SMD= 0.04; 95% CI: -0.19-0.26).

Conclusions:

  • The COVID-19 pandemic is associated with increased STEMI patient mortality and treatment delays.
  • Strict infection control measures during the pandemic may have contributed to these adverse outcomes.
  • Longer follow-up studies are recommended to further investigate STEMI patient outcomes.
Abstract

Related Concept Videos

Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
3
Acute Coronary SyndromeI: Introduction01:30

Acute Coronary SyndromeI: Introduction

Acute Coronary Syndrome (ACS) encompasses a spectrum of heart conditions caused by sudden obstruction of coronary arteries, typically resulting from the rupture of an atherosclerotic plaque and subsequent thrombus (blood clot) formation. This obstruction can lead to partial or complete blockage of blood flow, causing varying degrees of myocardial ischemia or infarction.ACS includes the following clinical entities:Unstable Angina (UA)Non-ST-Elevation Myocardial Infarction (NSTEMI)ST-Elevation...
3
Acute Coronary Syndrome III: Diagnostic studies01:30

Acute Coronary Syndrome III: Diagnostic studies

Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
3
Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
2
Coronary Artery Disease V: Surgical Management01:27

Coronary Artery Disease V: Surgical Management

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
3
Myocarditis IV: Nursing Management01:22

Myocarditis IV: Nursing Management

Myocarditis is an inflammatory condition of the myocardium requiring meticulous nursing management for optimal patient outcomes. Effective management begins with a thorough assessment of the patient's medical history, paying close attention to past infections, autoimmune disorders, travel history, and exposure to toxins or drugs. Recent viral infections and systemic diseases are particularly relevant due to their potential role in triggering myocarditis.Physical Examination and MonitoringThe...
2